Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 19/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25390011 | 0.87 | GRM5 (0.34) | GRM5NPC1RAB9A | |
| SCHEMBL1503764 | 0.84 | GRM5 (0.33) | GRM5NPC1RAB9A | |
| SCHEMBL28895700 | 0.82 | GRM5 (0.44) | GRM5NPC1RAB9A | |
| SCHEMBL175426 | 0.82 | RAD52 (0.53) | GRM5NPC1RAB9A | |
| SCHEMBL22396285 | 0.82 | GRM5 (0.44) | GRM5NPC1RAB9A | |
| SCHEMBL3441402 | 0.80 | NPC1 (0.45) | GRM5NPC1RAB9A | |
| SCHEMBL5779792 | 0.80 | GRM5 (0.42) | GRM5NPC1RAB9A | |
| SCHEMBL28371109 | 0.78 | NPC1 (0.44) | GRM5NPC1RAB9A | |
| SCHEMBL25345358 | 0.78 | GRM5 (0.53) | GRM5 | |
| SCHEMBL165650 | 0.78 | GRAMD1A (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| CN-110582493-B | Benzoxazole derivatives as immunomodulators | 因赛特公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-116115764-A | Tetrahydroimidazo [4,5-C ] pyridine derivatives as PD-L1 internalization inducers | 因赛特公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-109689647-B | Bicyclic heteroaryl substituted compounds | 百时美施贵宝公司 | 2023-01-20 | — | — | CN | disclosed |
| CN-110267953-B | Tetrahydroimidazo [4,5-C ] pyridine derivatives as inducers of PD-L1 internalization | 因赛特公司 | 2022-12-20 | — | — | CN | disclosed |
| CN-115315423-A | Substituted aryl compounds | 先声药业有限公司 | 2022-11-08 | — | — | CN | disclosed |
| CN-114728926-A | ROCK inhibitor and preparation method and application thereof | 武汉朗来科技发展有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| CN-108699038-B | Spirocyclic heptane salicylamides and related compounds as Rock inhibitors | 百时美施贵宝公司 | 2021-04-16 | — | — | CN | disclosed |
| CN-112566905-A | Substituted phenyl propenyl pyridine derivatives, preparation method and medical application thereof | 上海海雁医药科技有限公司 | 2021-03-26 | — | — | CN | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2007111904-A2 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007106349-A2 | PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129371-A1 | Novel ethylenediamine derivatives | C1R, C9, C1S | GRM5 2706/4885NPC1 3135/4885RAB9A 3871/4885 |
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | F2, F2RL3, F12 | GRM5 3779/4885NPC1 2194/4885RAB9A 748/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | GRM5 2219/4885NPC1 3358/4885RAB9A 3294/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | GRM5 2219/4885NPC1 3358/4885RAB9A 3294/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | GRM5 2219/4885NPC1 3358/4885RAB9A 3294/4885 |
| US-20070254868-A1 | C-MET protein kinase inhibitors | MET, PRKCH, ABL1 | GRM5 1526/4885NPC1 1406/4885RAB9A 2113/4885 |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, F12 | GRM5 3779/4885NPC1 2194/4885RAB9A 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.